Form 4: Journey Medical Director Granted 20,000 RSUs

Journey Medical Corp Director Michael Cooper Pearce was granted 20,000 restricted stock units, vesting over three years.

Summary

• Michael Cooper Pearce, a Director of Journey Medical Corp (DERM), was granted 20,000 restricted stock units (RSUs) on August 5, 2025.
• The RSUs were granted at a price of $0 per share.
• These RSUs will vest in three annual installments: 6,667 shares on August 5, 2028, 6,667 shares on August 5, 2029, and 6,666 shares on August 5, 2030.
• Following this transaction, Michael Cooper Pearce beneficially owns 57,173 shares, which includes these newly granted RSUs and previously held restricted stock units.
• The grant was made pursuant to the Issuer's 2015 Stock Plan, as amended.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates continued alignment of a director's interests with the company's long-term performance through equity compensation.

Positives

• The grant of 20,000 restricted stock units to a Director aligns management's interests with long-term shareholder value.
• Equity compensation at a $0 price indicates a direct incentive for future performance and stock appreciation.

Future Outlook

The vesting schedule for the restricted stock units extends through August 2030, indicating a long-term commitment and incentive structure for the director.

Industry Context

This Form 4 filing is a standard disclosure of an insider equity grant, common across all industries as a form of executive and director compensation to align interests with company performance.

Related Party Transactions

• The grant of 20,000 restricted stock units to Director Michael Cooper Pearce is a related party transaction, as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of equity to a director helps align their interests with those of shareholders, potentially encouraging decisions that enhance long-term stock value.
• Employees: While not directly impacting employees, such compensation practices can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• Vesting of 6,667 restricted stock units on August 5, 2028.
• Vesting of 6,667 restricted stock units on August 5, 2029.
• Vesting of 6,666 restricted stock units on August 5, 2030.

Key Dates

Keywords

Journey Medical Corp, DERM, Form 4, Insider Transaction, Restricted Stock Units, RSU Grant, Director Compensation, Equity Compensation, Stock Plan